Advertisement
Product › Details
Zevtera™ (ceftobiprole medocaril)
Next higher product group | ceftobiprole | |
Status | 2014-12-05 sales start | |
Organisation | Basilea Pharmaceutica Ltd. (SIX: BSLN) | |
Group | Basilea (Group) | |
Record changed: 2024-04-07 |
Advertisement
More documents for Zevtera™ (ceftobiprole medocaril)
- [1] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
- [2] Basilea Pharmaceutica Ltd.. (2/27/18). "Press Release: Basilea Reports Significantly Improved Financial Results in 2017". Basel....
- [3] Basilea Pharmaceutica Ltd.. (2/21/18). "Press Release: Basilea's CEO Ronald Scott Will Retire. Chief Commercial Officer David Veitch Named as Successor – Changes in the Board of Directors". Basel....
- [4] Basilea Pharmaceutica Ltd.. (9/28/17). "Press Release: Basilea Announces License Agreement for Antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top